Any of these blue chip stocks would be solid long-term picks. One of them, however, is especially underestimated right now.

Vertex Pharmaceuticals (VRTX 1.39%) is making its biggest bet in years. On Monday, the company agreed to acquire Crinetics ...

Shares of Meta Platforms (META +2.59%) were heading lower last month as a slew of concerns mounted for the social media giant ...

Its acquisition of Cursor demonstrates that it recognizes the importance of creating a robust AI platform -- but it also ...

JPMorgan analyst Chris Schott reiterated his overweight (read: buy) rating on Eli Lilly's stock and boosted his share price ...

Well before market open that day, Palantir reported that it had agreed to an "enterprise expansion agreement" with Mexico's ...

According to data from S&P Global Market Intelligence, the stock lost 17% last month. As you can see from the chart below, the stock was heading lower over most of the month. Netflix kicked off the ...

Based on Rivian’s closing price of $20.14 per share on July 6, the offering would raise slightly over $1.5 billion. Here’s ...

Ives assigned SpaceX an outperform rating and a 12-month price target of $190. This implies roughly 18% upside from where it ...

Microsoft (MSFT +0.59%) has a massive business with many products and services. And while its overall operations continue to ...

And yet, that's not how people statistically make the most money in the stock market. Fidelity research shows that ...

Samsung posted a 19-fold profit increase and investors said "cool, we're selling anyway," dragging the Nasdaq Composite index ...